{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:34Z","timestamp":1790701534791,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.retram.2026.103601","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:11:23Z","timestamp":1783062683000},"page":"103601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of CD19 CAR T-cell therapy in relapsed\/refractory follicular lymphoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3484-9952","authenticated-orcid":false,"given":"Leen","family":"Haj Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly Adel","family":"Ata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Alshaboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awab","family":"Alani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Askar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2026.103601_bib0001","series-title":"Lyon: international agency for research on cancer","first-page":"585","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2017"},{"issue":"1","key":"10.1016\/j.retram.2026.103601_bib0002","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primer"},{"issue":"31","key":"10.1016\/j.retram.2026.103601_bib0003","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of Rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.retram.2026.103601_bib0004","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.retram.2026.103601_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11864-018-0550-0","article-title":"Follicular lymphoma: past, present, and future","volume":"19","author":"Becnel","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.1016\/j.retram.2026.103601_bib0006","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ejh.14401","article-title":"Relapsed\/refractory follicular lymphoma: current advances and emerging perspectives","volume":"114","author":"Carid\u00e0","year":"2025","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.retram.2026.103601_bib0007","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4274\/tjh.galenos.2024.2024.0015","article-title":"Advancements in the management of follicular lymphoma: a comprehensive review","volume":"41","author":"Merryman","year":"2024","journal-title":"Turk J Hematol"},{"issue":"17","key":"10.1016\/j.retram.2026.103601_bib0008","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2026.103601_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1414244","article-title":"Survival analysis of a 16-year cohort of follicular lymphoma patients receiving systemic treatment in Brazil","volume":"15","author":"Azevedo","year":"2025","journal-title":"Front Pharmacol"},{"issue":"3602","key":"10.1016\/j.retram.2026.103601_bib0010","article-title":"Follicular lymphoma: a focus on current and emerging therapies","year":"2022","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.retram.2026.103601_bib0011","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3904\/kjim.2024.279","article-title":"Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances","volume":"40","author":"Kridel","year":"2025","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1016\/j.retram.2026.103601_bib0012","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.retram.2026.103601_bib0013","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.retram.2026.103601_bib0014","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1007\/s00277-025-06575-9","article-title":"Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review","volume":"104","author":"Abrisqueta","year":"2025","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.retram.2026.103601_bib0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.retram.2026.103601_bib0016","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus Rituximab or CHOP plus131 I-Tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.retram.2026.103601_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/cancers13010038","article-title":"The influence of chimeric antigen receptor structural domains on clinical outcomes and associated toxicities","volume":"13","author":"Davey","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.retram.2026.103601_bib0018","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oncolo\/oyac054","article-title":"FDA approval summary: axicabtagene Ciloleucel for relapsed or refractory follicular lymphoma","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.retram.2026.103601_bib0019","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.retram.2026.103601_bib0020","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.retram.2026.103601_bib0021","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.retram.2026.103601_bib0022","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jclinepi.2012.11.011","article-title":"Simple search techniques in PubMed are potentially suitable for evaluating the completeness of systematic reviews","volume":"66","author":"Waffenschmidt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.retram.2026.103601_bib0023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jclinepi.2016.03.004","article-title":"Complementary approaches to searching MEDLINE may be sufficient for updating systematic reviews","volume":"78","author":"Sampson","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.retram.2026.103601_bib0024","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.retram.2026.103601_bib0025","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.retram.2026.103601_bib0026","series-title":"Quality assessment tool for case series studies [Internet]","year":"2021"},{"issue":"4","key":"10.1016\/j.retram.2026.103601_bib0027","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/jebm.12445","article-title":"The Freeman\u2013Tukey double arcsine transformation for the meta-analysis of proportions: recent criticisms were seriously misleading","volume":"14","author":"Doi","year":"2021","journal-title":"J Evid-Based Med"},{"key":"10.1016\/j.retram.2026.103601_bib0028","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jclinepi.2020.09.044","article-title":"Quality versus risk-of-bias assessment in clinical research","volume":"129","author":"Furuya-Kanamori","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.retram.2026.103601_bib0029","doi-asserted-by":"crossref","DOI":"10.1111\/jebm.70120","article-title":"Six entrenched misconceptions about meta-analysis models","volume":"19","author":"Elmakaty","year":"2026","journal-title":"J Evid-Based Med"},{"issue":"3","key":"10.1016\/j.retram.2026.103601_bib0030","doi-asserted-by":"crossref","DOI":"10.1111\/jebm.70063","article-title":"Examining and interpreting Doi plot asymmetry in meta-analyses of randomized controlled trials","volume":"18","author":"Furuya-Kanamori","year":"2025","journal-title":"J Evid-Based Med"},{"issue":"8","key":"10.1016\/j.retram.2026.103601_bib0031","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jclinepi.2014.03.003","article-title":"In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias","volume":"67","author":"Hunter","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.retram.2026.103601_bib0032","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2026.103601_bib0033","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/bjh.20122","article-title":"Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study","volume":"207","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.retram.2026.103601_bib0034","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.retram.2026.103601_bib0035","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/jama.2024.1011","article-title":"FDA adds boxed warning to CAR T-cell therapies, but says benefits outweigh risks of secondary cancers","volume":"331","author":"Suran","year":"2024","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.retram.2026.103601_bib0036","first-page":"863","article-title":"Malignancies after chimeric antigen receptor T cell therapy","volume":"31","author":"Mohty","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"20","key":"10.1016\/j.retram.2026.103601_bib0037","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-Cell Therapy: a systematic review and meta-analysis of 5517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.retram.2026.103601_bib0038","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.gt.3302243","article-title":"Insertional oncogenesis in gene therapy: how much of a risk?","volume":"11","author":"Sadelain","year":"2004","journal-title":"Gene Ther"},{"issue":"7","key":"10.1016\/j.retram.2026.103601_bib0039","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103601_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1384600","article-title":"The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy","volume":"14","author":"Jacobs","year":"2024","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.retram.2026.103601_bib0041","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2026.103601_bib0042","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.retram.2026.103601_bib0043","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.retram.2026.103601_bib0044","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2026.103601_bib0045","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10524","key":"10.1016\/j.retram.2026.103601_bib0046","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:30:16Z","timestamp":1790699416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2452318626000371"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103601","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of CD19 CAR T-cell therapy in relapsed\/refractory follicular lymphoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103601"}}